KO

KOMIPHARM INTERNATIONAL CO., LTD.

Develops animal health products and novel drugs for human cancer and autoimmune diseases.

041960 | KO

Overview

Corporate Details

ISIN(s):
KR7041960006
LEI:
Country:
South Korea
Address:
경기도 시흥시 경제로 17, 시흥시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Komipharm International Co., Ltd. is a biopharmaceutical company with core operations in animal health and a strategic focus on human therapeutics. The company develops, manufactures, and sells a diverse portfolio of veterinary products, including vaccines, pharmaceuticals, and disinfectants for livestock, poultry, and companion animals. Leveraging over 50 years of industry experience, Komipharm is also engaged in the research and development of novel drugs for human use. Its pharmaceutical pipeline concentrates on creating therapeutic agents for challenging indications such as cancer pain and autoimmune diseases, as part of its strategy to expand into the global bio-industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(약식)
Korean 122.0 KB
2025-09-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 78.6 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-08-06 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-07-30 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 61.3 KB
2025-07-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.8 KB
2025-06-20 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 37.4 KB
2025-06-20 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.7 KB
2025-05-27 00:00
Capital/Financing Update
주요사항보고서(제3자의전환사채매수선택권행사)
Korean 23.3 KB
2025-05-14 00:00
Annual Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-29 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 14.4 KB
2025-04-23 00:00
Share Issue/Capital Change
전환청구권행사
Korean 11.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 31.6 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.1 KB
2025-03-26 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.7 KB

Automate Your Workflow. Get a real-time feed of all KOMIPHARM INTERNATIONAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOMIPHARM INTERNATIONAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOMIPHARM INTERNATIONAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.